- Home
- PIM vs FDMT Comparison
PIM vs FDMT Comparison
Compare PIM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- FDMT
- Stock Information
- Founded
- PIM 1988
- FDMT 2013
- Country
- PIM United States
- FDMT United States
- Employees
- PIM N/A
- FDMT N/A
- Industry
- PIM Finance Companies
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- FDMT Health Care
- Exchange
- PIM Nasdaq
- FDMT Nasdaq
- Market Cap
- PIM 161.4M
- FDMT 192.2M
- IPO Year
- PIM N/A
- FDMT 2020
- Fundamental
- Price
- PIM $3.31
- FDMT $7.09
- Analyst Decision
- PIM
- FDMT Buy
- Analyst Count
- PIM 0
- FDMT 9
- Target Price
- PIM N/A
- FDMT $30.63
- AVG Volume (30 Days)
- PIM 57.5K
- FDMT 2.6M
- Earning Date
- PIM 01-01-0001
- FDMT 08-11-2025
- Dividend Yield
- PIM 8.28%
- FDMT N/A
- EPS Growth
- PIM N/A
- FDMT N/A
- EPS
- PIM 0.05
- FDMT N/A
- Revenue
- PIM N/A
- FDMT $33,000.00
- Revenue This Year
- PIM N/A
- FDMT $9,921.62
- Revenue Next Year
- PIM N/A
- FDMT N/A
- P/E Ratio
- PIM $63.80
- FDMT N/A
- Revenue Growth
- PIM N/A
- FDMT N/A
- 52 Week Low
- PIM $2.90
- FDMT $2.24
- 52 Week High
- PIM $3.28
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- PIM 43.97
- FDMT 65.24
- Support Level
- PIM $3.32
- FDMT $6.35
- Resistance Level
- PIM $3.35
- FDMT $7.59
- Average True Range (ATR)
- PIM 0.03
- FDMT 0.59
- MACD
- PIM -0.00
- FDMT 0.05
- Stochastic Oscillator
- PIM 12.50
- FDMT 78.81
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.